RUBINSTEIN JULIE sold $897K of ADPT
RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.38–$26.30, $0.90M total) across 6 trades over 2026-10-22 to 2026-10-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may prompt short‑term price weakness but likely has limited long‑term effect.
Market read
Insider sale of ~$0.9M by a senior executive; modest relevance for traders monitoring ADPT.
What to watch
Potential upcoming regulatory or clinical milestones that may offset the sell‑off.
Background
Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.
Ticker impact
President and COO Julie Rubinstein sold 35,643 shares for $897K via a 10b5-1 plan, reducing her stake to 377,802 shares.
likely downward pressure as the market prices in the insider sell
A sizable insider sale by a top executive, even via a pre‑arranged plan, often triggers short‑term selling pressure.
Market effects
Minimal impact on the broader biotech sector; the sale is company‑specific.
No regional effect; confined to US markets.
Limited global relevance; only affects Adaptive Biotechnologies investors.
Counterpoint
The sale could be purely procedural under the 10b5‑1 plan, not reflecting negative sentiment.
Key entities
- personJulie Rubinstein
President and COO of Adaptive Biotechnologies
- companyAdaptive Biotechnologies Corp
US‑listed biotech firm (NASDAQ: ADPT)
